A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. / Knorr, Ulla; Vinberg, Maj; Gade, Anders; Winkel, Per; Gluud, Christian; Wetterslev, Jørn; Gether, Ulrik; Kessing, Lars.
I: Therapeutic Advances in Psychopharmacology, Bind 1, Nr. 5, 2011, s. 133-44.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression
AU - Knorr, Ulla
AU - Vinberg, Maj
AU - Gade, Anders
AU - Winkel, Per
AU - Gluud, Christian
AU - Wetterslev, Jørn
AU - Gether, Ulrik
AU - Kessing, Lars
PY - 2011
Y1 - 2011
N2 - The effect of selective serotonin receptor inhibitors (SSRIs) on healthy individuals remains unclear. The aim of the trial was to evaluate the effect of the SSRI escitalopram on cognitive function in healthy first-degree relatives of patients with major depressive disorder (FDRs). A total of 80 FDRs were randomized to escitalopram (10 mg/day) (n = 41) versus placebo (n = 39) for 4 weeks. Neuropsychological tests and ratings of mood were applied at entry (T0) and at 4 weeks (T4). The main outcome measure was calculated as the change (T4-T0) in a general cognition score, which was the standardized mean of 13 test measures. Mean change in the general cognition score was not significantly increased with escitalopram compared with placebo (p = 0.37) or for any of the specific tests. In univariate analyses no statistically significant correlations were found between change in the general cognitive score and the variables age, sex, Hamilton depression score 17 items, Danish Adult Reading Test-45, and plasma escitalopram levels, respectively. These results suggest that treatment with escitalopram does not improve or impair cognitive function in FDRs. Improvement in cognitive function following treatment of depressed patients with SSRIs seems to be related to the effects on depressive symptoms rather than to a direct effect of the SSRI.
AB - The effect of selective serotonin receptor inhibitors (SSRIs) on healthy individuals remains unclear. The aim of the trial was to evaluate the effect of the SSRI escitalopram on cognitive function in healthy first-degree relatives of patients with major depressive disorder (FDRs). A total of 80 FDRs were randomized to escitalopram (10 mg/day) (n = 41) versus placebo (n = 39) for 4 weeks. Neuropsychological tests and ratings of mood were applied at entry (T0) and at 4 weeks (T4). The main outcome measure was calculated as the change (T4-T0) in a general cognition score, which was the standardized mean of 13 test measures. Mean change in the general cognition score was not significantly increased with escitalopram compared with placebo (p = 0.37) or for any of the specific tests. In univariate analyses no statistically significant correlations were found between change in the general cognitive score and the variables age, sex, Hamilton depression score 17 items, Danish Adult Reading Test-45, and plasma escitalopram levels, respectively. These results suggest that treatment with escitalopram does not improve or impair cognitive function in FDRs. Improvement in cognitive function following treatment of depressed patients with SSRIs seems to be related to the effects on depressive symptoms rather than to a direct effect of the SSRI.
U2 - 10.1177/2045125311422591
DO - 10.1177/2045125311422591
M3 - Journal article
C2 - 23983938
VL - 1
SP - 133
EP - 144
JO - Therapeutic Advances in Psychopharmacology
JF - Therapeutic Advances in Psychopharmacology
SN - 2045-1253
IS - 5
ER -
ID: 138813924